

PRESS RELEASE

Barry Frankel is new Senior Vice President Strategy and Business Development of MetrioPharm AG

- Having already advised MetrioPharm AG strategically, Frankel joins the company in 2019 as Senior Vice President Strategy and Business Development.
- He previously worked for Pfizer Pharmaceuticals and was President of S.J. Weinstein Associates.

Zurich, April 10, 2019. MetrioPharm AG, a pharmaceutical development company, welcomes Barry Frankel as a new team member. Barry Frankel had already advised the company on strategic issues since 2018 and will assume the position of Senior Vice President Strategy and Business Development as of 2019.

He will be responsible for the future development strategy and Business Development. Negotiations with potential pharmaceutical partners will be a focus of his work.

Barry Frankel is the founder of Frankel Group LLC, a global life science strategy consulting firm with offices in New York NY, Cambridge MA and Tel Aviv. He served as a Director of Pfizer Pharmaceuticals and as a Senior Research Officer of Citibank Investment Management Group, responsible for investment recommendations in the life science industry. Barry Frankel was also a partner and president of SJ Weinstein Associates Inc, a healthcare advertising and marketing strategy firm.

Dr. Wolfgang Brysch, CEO of MetrioPharm AG: „Barry has worked in a senior position for large companies in the pharmaceutical industry and has an excellent network. We have come to know him as an experienced negotiator and outstanding strategist. Barry is the ideal addition to our team for the tasks ahead and we look forward to working with him”.

Barry Frankel: “When I met with the Board, with the CEO and with the senior management team, I was struck by their level of expertise and their level of commitment to the same mission to create a new business model in healthcare. The MetrioPharm team has a truly unique blend of professionalism and passion and I am happy to become a part of that.”

You can read a longer conversation with Barry Frankel on our [MetrioPharm Blog](#).

PRESS RELEASE

About MetrioPharm

MetrioPharm AG is a pharmaceutical development company developing drugs for chronic inflammatory diseases such as psoriasis, arthritis, and multiple sclerosis. Such chronic diseases pose the greatest individual health risk. The goal of MetrioPharm AG is to make the therapy of chronic inflammatory diseases more effective and more tolerable. We hope to achieve a healthspan expansion for patients: We want to stop the progression of chronic inflammatory diseases as early as possible and significantly prolong the healthy lifespan of millions of people.

MetrioPharm AG was founded in 2007 and is headquartered in Zurich with research facilities in Berlin.

About MP1032

MP1032 is the lead compound of a class of proprietary immune modulators developed by MetrioPharm. MP1032 is believed to modulate the oxidative stress-mediated activation state of macrophages and downregulate the M1 state. In contrast to other immune-modulating and disease-modifying drugs, MP1032 does not impact T-cells and preferentially affects macrophages at the sites of inflammation. MP1032 has shown anti-inflammatory activity in animal models of disease and a favorable toxicology profile in pre-clinical studies.

For the first Phase II study with MP1032, the indication psoriasis was selected because this immune-induced inflammatory disease is regarded as a so-called »door-opener indication«. Successes in the treatment of psoriasis have already led to first indications of promise for use in other chronic inflammatory diseases, such as arthritis and multiple sclerosis.

Forward-looking statements

This press release contains forward-looking statements that involve risks and uncertainties and are consistent with MetrioPharm's assessment as of the date of this release. Such forward-looking statements are neither promises nor guarantees, but are subject to numerous risks and uncertainties, many of which are beyond MetrioPharm's control, that could cause actual results to differ materially from those contemplated in these forward-looking statements. MetrioPharm does not assume any obligation to update forward-looking statements with respect to changed expectations or new events, conditions or circumstances on which these statements are based. A liability or guarantee and, if applicable, claims for topicality, correctness and completeness of these data and information are excluded and cannot be derived either explicitly or impliedly.

PRESS RELEASE

Your Contact

Eva Brysch

Head of Investor Relations & Corporate Communications

MetrioPharm AG
Bleicherweg 45
CH-8002 Zurich

MetrioPharm Deutschland GmbH
Am Borsigturm 100
D-13507 Berlin

T +49 (0) 30 33 84 395 40

F +49 (0) 30 33 84 395 99

E invest@metriopharm.com

W www.metriopharm.com

